Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Palisade Bio, Inc. (PALI)
USD2.03
+0.10 (+5.41%)
US NASDAQ Healthcare Biotechnology
Address
5800 Armada Drive 92008
Carlsbad, CA, US
Carlsbad, CA, US
CEO
J. D. Finley
Website
palisadebio.com
IPO
2007-03-30
CIK 1357459 ISIN US6963894026
Description
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
News Sentiment (7d)
3 articles
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Seneca | SNCA | 2020-12-23 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.03
+0.10 (+5.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
1.51
Float Shares
163.10M
Free Float %
97.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.03% | -3.52% | +5.49% | +10.34% | -5.88% | -18.30% | +149.67% | -91.95% | -99.95% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
2.03
Low
1.50
-26.3%
Consensus
1.50
-26.3%
Median
1.50
-26.3%
High
1.50
-26.3%
DCF (Unlevered)
2.39
+17.3%
DCF (Levered)
2.39
+17.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
1.50
-26.3%
|
Quality scores
Altman Z-Score
31.19
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+97.1% ★ Q1'26: +89.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3,831.5% Q1'26: +4,271.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.4K
est: 10.0K (+4.2%)
|
16.2K
est: 5.0K (+224.9%)
|
260.0K
est: 10.0K (+2,500.0%)
|
260.0K
est: 10.0K (+2,500.0%)
|
—
est: 250.0K (-100.0%)
|
250.0K
est: 250.0K (+0.0%)
|
—
est: 8.21M (-100.0%)
|
—
est: 12.15M (-100.0%)
|
27.87M
27.87M – 27.87M
+129.4% YoY
|
47.71M
47.71M – 47.71M
+71.2% YoY
|
81.03M
81.03M – 81.03M
+69.8% YoY
|
207.66M
207.66M – 207.66M
+156.3% YoY
|
303.04M
303.04M – 303.04M
+45.9% YoY
|
| EBITDA |
-18.74M
est: 6.0K (-312,466.7%)
|
-19.60M
est: 3.0K (-653,300.0%)
|
-15.22M
est: 6.0K (-253,733.3%)
|
-4.73M
est: 6.0K (-78,950.0%)
|
-14.24M
est: 150.0K (-9,596.0%)
|
-12.28M
est: 150.0K (-8,287.3%)
|
-14.42M
est: 4.93M (-392.7%)
|
-18.06M
est: 7.29M (-347.7%)
|
16.72M
16.72M – 16.72M
+129.4% YoY
|
28.63M
28.63M – 28.63M
+71.2% YoY
|
48.62M
48.62M – 48.62M
+69.8% YoY
|
124.60M
124.60M – 124.60M
+156.3% YoY
|
181.82M
181.82M – 181.82M
+45.9% YoY
|
| EBIT |
-19.09M
est: 6.0K (-318,233.3%)
|
-19.93M
est: 3.0K (-664,533.3%)
|
-15.51M
est: 6.0K (-258,550.0%)
|
-4.92M
est: 6.0K (-82,050.0%)
|
-14.25M
est: 150.0K (-9,598.0%)
|
-12.29M
est: 150.0K (-8,290.0%)
|
-14.43M
est: 4.93M (-392.7%)
|
-18.06M
est: 7.29M (-347.7%)
|
16.72M
16.72M – 16.72M
+129.4% YoY
|
28.63M
28.63M – 28.63M
+71.2% YoY
|
48.62M
48.62M – 48.62M
+69.8% YoY
|
124.60M
124.60M – 124.60M
+156.3% YoY
|
181.82M
181.82M – 181.82M
+45.9% YoY
|
| Net Income |
-20.90M
est: -405.90B (+100.0%)
|
-21.08M
est: -306.49B (+100.0%)
|
-15.67M
est: -3.74T (+100.0%)
|
-4.93M
est: -3.71T (+100.0%)
|
-14.26M
est: -455.17M (+96.9%)
|
-12.30M
est: -39.85M (+69.1%)
|
-14.44M
est: -649.03M (+97.8%)
|
-16.78M
est: -16.78M (+0.0%)
|
-9.72M
-15.06M – -4.39M
+42.0% YoY
|
-12.02M
-16.44M – -7.59M
-23.6% YoY
|
-16.42M
-17.26M – -15.59M
-36.7% YoY
|
-17.63M
-17.63M – -17.63M
-7.3% YoY
|
4.64M
4.64M – 4.64M
+126.3% YoY
|
| SGA |
6.18M
est: 57.6K (+10,633.1%)
|
7.00M
est: 28.8K (+24,205.7%)
|
5.18M
est: 57.6K (+8,894.0%)
|
4.37M
est: 57.6K (+7,489.9%)
|
8.76M
est: 1.44M (+508.4%)
|
6.20M
est: 1.44M (+330.6%)
|
5.80M
est: 47.32M (-87.8%)
|
7.86M
est: 69.99M (-88.8%)
|
160.58M
160.58M – 160.58M
+129.4% YoY
|
274.90M
274.90M – 274.90M
+71.2% YoY
|
466.87M
466.87M – 466.87M
+69.8% YoY
|
1.20B
1.20B – 1.20B
+156.3% YoY
|
1.75B
1.75B – 1.75B
+45.9% YoY
|
| EPS |
-197.36
est: -286,650.00 (+99.9%)
|
-126.11
est: -216,450.00 (+99.9%)
|
-71.59
est: -2,644,200.00 (+100.0%)
|
-18.02
est: -2,620,800.00 (+100.0%)
|
-16.53
est: -321.45 (+94.9%)
|
-27.01
est: -28.14 (+4.0%)
|
-10.19
est: -11.66 (+12.6%)
|
-0.30
est: -0.54 (+44.9%)
|
-0.20
-0.27 – -0.08
+62.7% YoY
|
-0.24
-0.30 – -0.14
-17.6% YoY
|
-0.30
-0.31 – -0.28
-24.7% YoY
|
-0.32
-0.32 – -0.32
-6.4% YoY
|
0.08
0.08 – 0.08
+126.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.85M
OE per share TTM
-1.40
Owner's Yield
-10.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
467.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
4.69M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B. Asher | 7.60M | 9.99% | — | 7.60M | — | 7.60M | HC | United States of America | 2022-08-22 | ↗ |
| 2 | Capital LLC | 7.60M | 9.99% | — | 7.60M | — | 7.60M | OO | United States of America | 2022-08-22 | ↗ |
| 3 | P. Kopin | 7.60M | 9.99% | — | 7.60M | — | 7.60M | HC | United States of America | 2022-08-22 | ↗ |
| 4 | Kent C. McCarthy | 2.39M | 17.03% | — | 1.56M | — | 1.56M | IN | Cayman Islands | 2019-01-07 | ↗ |
| 5 | Yuma Regional Medical Center | 2.25M | 19.00% | 2.25M | — | 2.25M | 11.00 | CO | — | 2021-08-30 | ↗ |
| 6 | Monarch GP LLC | 2.19M | 9.75% | — | 381.5K | — | 381.5K | HC, OO | Cayman Islands | 2020-01-21 | ↗ |
| 7 | Armistice Capital Master Fund Ltd. | 908.6K | 4.99% | — | 908.6K | — | 908.6K | CO | Delaware | 2020-05-29 | ↗ |
| 8 | Altium Capital Management, LP | 858.9K | 9.99% | — | 858.9K | — | — | IA, PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 9 | Altium Growth Fund, LP | 858.9K | 9.99% | — | 858.9K | — | — | PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 10 | Altium Growth GP, LLC | 858.9K | 9.99% | — | 858.9K | — | — | OO | Delaware, United States of America | 2022-02-14 | ↗ |
| 11 | Hudson Bay Capital Management LP | 858.0K | 4.73% | — | 858.0K | — | — | PN | State of Delaware | 2021-02-11 | ↗ |
| 12 | Sander Gerber | 858.0K | 4.73% | — | 858.0K | — | — | IN | United States | 2021-02-11 | ↗ |
| 13 | Jeff Easton | 743.3K | 7.90% | 743.3K | — | 743.3K | — | IN | Delaware | 2023-09-15 | ↗ |
| 14 | Lind Global Fund II LP | 743.3K | 7.90% | 743.3K | — | 743.3K | — | PN | Delaware | 2023-09-15 | ↗ |
| 15 | Lind Global Partners II LLC | 743.3K | 7.90% | 743.3K | — | 743.3K | — | OO | Delaware | 2023-09-15 | ↗ |
| 16 | L1 Capital Global Opportunities Master Fund Ltd. | 585.0K | 6.40% | 585.0K | — | — | — | FI | Cayman Islands | 2023-09-15 | ↗ |
| 17 | Daniel B. Asher | 196.1K | 1.40% | — | 196.1K | — | 196.1K | HC, IN | United States of America | 2022-02-11 | ↗ |
| 18 | Intracoastal Capital LLC | 196.1K | 1.40% | — | 196.1K | — | 196.1K | OO | Delaware | 2022-02-11 | ↗ |
| 19 | Mitchell P. Kopin | 196.1K | 1.40% | — | 196.1K | — | 196.1K | HC, IN | United States of America | 2022-02-11 | ↗ |
| 20 | 13-3127734 | 167.5K | 0.97% | 167.5K | — | 167.5K | — | HC | Delaware | 2021-02-11 | ↗ |
| 21 | 26-0385758 | 167.5K | 0.97% | 167.5K | — | 167.5K | — | IA | Delaware | 2021-02-11 | ↗ |
| 22 | Armistice Capital, LLC | 125.7K | 9.99% | — | 125.7K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 23 | Steven Boyd | 125.7K | 9.99% | — | 125.7K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-74 vs prev Q
New positions
3
Closed positions
77
Increased
7
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 12.05M +12.1M (+100.0%) | 28.32M +28.3M (+100.0%) | 161.23% +161.228 pp | 0.50% +0.505 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 2 | COMMODORE CAPITAL LP | 11.45M +11.4M (+100.0%) | 26.90M +26.9M (+100.0%) | 153.13% +153.133 pp | 1.79% +1.790 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 3 | JANUS HENDERSON GROUP PLC | 10.54M +10.5M (+100.0%) | 24.82M +24.8M (+100.0%) | 141.03% +141.029 pp | 0.01% +0.011 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 4 | POINT72 ASSET MANAGEMENT, L.P. | 10.50M +10.5M (+100.0%) | 24.66M +24.7M (+100.0%) | 140.43% +140.425 pp | 0.03% +0.028 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 5 | OCTAGON CAPITAL ADVISORS LP | 9.57M +9.6M (+100.0%) | 22.48M +22.5M (+100.0%) | 128.02% +128.018 pp | 2.73% +2.730 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 7.12M +7.1M (+100.0%) | 16.74M +16.7M (+100.0%) | 95.32% +95.320 pp | 0.17% +0.172 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 7 | AMERIPRISE FINANCIAL INC | 6.91M +6.9M (+100.0%) | 16.24M +16.2M (+100.0%) | 92.47% +92.472 pp | 0.00% +0.004 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 8 | EVERSEPT PARTNERS, LP | 5.39M +5.4M (+100.0%) | 12.67M +12.7M (+100.0%) | 72.14% +72.138 pp | 0.64% +0.639 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 9 | FRANKLIN RESOURCES INC | 5.09M +5.1M (+100.0%) | 11.97M +12.0M (+100.0%) | 68.14% +68.138 pp | 0.00% +0.003 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 10 | BOXER CAPITAL MANAGEMENT, LLC | 4.80M +4.8M (+100.0%) | 11.28M +11.3M (+100.0%) | 64.22% +64.222 pp | 2.47% +2.469 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 11 | B GROUP, INC. | 4.50M +4.5M (+100.0%) | 10.58M +10.6M (+100.0%) | 60.21% +60.210 pp | 7.81% +7.808 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.50M +4.5M (+100.0%) | 10.58M +10.6M (+100.0%) | 60.21% +60.210 pp | 0.02% +0.016 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 13 | STEMPOINT CAPITAL LP | 4.19M +4.2M (+100.0%) | 9.85M +9.9M (+100.0%) | 56.09% +56.094 pp | 1.69% +1.689 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 14 | MORGAN STANLEY | 4.14M +4.1M (+47,967.4%) | 9.73M +9.7M (+131,290.9%) | 55.43% +55.310 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 7 qtrs — |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 2.38M +2.4M (+100.0%) | 5.60M +5.6M (+100.0%) | 31.88% +31.878 pp | 0.01% +0.009 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 16 | VIVO CAPITAL, LLC | 2.29M +2.3M (+100.0%) | 5.39M +5.4M (+100.0%) | 30.69% +30.688 pp | 0.35% +0.348 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 17 | VANGUARD GROUP INC | 2.12M +2.1M (+100.0%) | 4.97M +5.0M (+100.0%) | 28.31% +28.307 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 18 | ADAR1 CAPITAL MANAGEMENT, LLC | 2.00M +2.0M (+100.0%) | 4.71M +4.7M (+100.0%) | 26.82% +26.825 pp | 0.35% +0.346 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 19 | ARTIA GLOBAL PARTNERS LP | 1.99M +2.0M (+100.0%) | 4.68M +4.7M (+100.0%) | 26.66% +26.658 pp | 0.75% +0.747 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 20 | BLACKROCK, INC. | 1.88M +1.9M (+100.0%) | 4.42M +4.4M (+100.0%) | 25.15% +25.145 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 21 | ORBIMED ADVISORS LLC | 1.87M +1.9M (+100.0%) | 4.40M +4.4M (+100.0%) | 25.04% +25.039 pp | 0.09% +0.090 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 22 | CITADEL ADVISORS LLC | 1.70M +1.7M (+100.0%) | 4.00M +4.0M (+100.0%) | 22.76% +22.765 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.58M +1.6M (+100.0%) | 3.71M +3.7M (+100.0%) | 21.11% +21.112 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 24 | GEODE CAPITAL MANAGEMENT, LLC | 1.57M +1.5M (+5,780.7%) | 3.68M +3.7M (+15,984.4%) | 20.95% +20.589 pp | 0.00% +0.000 pp | USD2.33 +0.9% | 5 qtrs — |
| 25 | HIGHVISTA STRATEGIES LLC | 1.30M +1.3M (+100.0%) | 3.06M +3.1M (+100.0%) | 17.39% +17.394 pp | 0.79% +0.787 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 26 | EXOME ASSET MANAGEMENT LLC | 758.2K +758.2K (+100.0%) | 1.78M +1.8M (+100.0%) | 10.14% +10.145 pp | 0.85% +0.852 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 27 | PLATINUM INVESTMENT MANAGEMENT LTD | 664.1K +664.1K (+100.0%) | 1.56M +1.6M (+100.0%) | 8.89% +8.885 pp | 0.36% +0.361 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 28 | HUDSON BAY CAPITAL MANAGEMENT LP | 656.5K +656.5K (+100.0%) | 1.54M +1.5M (+100.0%) | 8.78% +8.783 pp | 0.01% +0.005 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 29 | STATE STREET CORP | 644.0K +644.0K (+100.0%) | 1.51M +1.5M (+100.0%) | 8.62% +8.617 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 30 | GOLDMAN SACHS GROUP INC | 557.6K +557.6K (+100.0%) | 1.31M +1.3M (+100.0%) | 7.46% +7.460 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 31 | PERSISTENT ASSET PARTNERS LTD | 416.0K +416.0K (+100.0%) | 977.7K +977.7K (+100.0%) | 5.57% +5.567 pp | 0.44% +0.439 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 32 | RESOLUTE CAPITAL ASSET PARTNERS LLC | 400.0K +400.0K (+100.0%) | 940.0K +940.0K (+100.0%) | 5.35% +5.352 pp | 0.45% +0.454 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 33 | SUPERSTRING CAPITAL MANAGEMENT LP | 367.1K +367.1K (+100.0%) | 862.7K +862.7K (+100.0%) | 4.91% +4.912 pp | 0.46% +0.462 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 34 | JANE STREET GROUP, LLC | 343.7K +343.7K (+100.0%) | 807.7K +807.7K (+100.0%) | 4.60% +4.599 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 35 | — | 327.5K +327.5K (+100.0%) | 769.6K +769.6K (+100.0%) | 4.38% +4.382 pp | 0.59% +0.585 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 36 | BALYASNY ASSET MANAGEMENT L.P. | 325.4K +325.4K (+100.0%) | 764.6K +764.6K (+100.0%) | 4.35% +4.353 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 37 | SQUAREPOINT OPS LLC | 322.1K +322.1K (+100.0%) | 756.9K +756.9K (+100.0%) | 4.31% +4.310 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 38 | BIT CAPITAL GMBH | 305.0K +305.0K (+100.0%) | 716.8K +716.8K (+100.0%) | 4.08% +4.081 pp | 0.03% +0.026 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 39 | MILLENNIUM MANAGEMENT LLC | 294.5K +294.5K (+100.0%) | 692.0K +692.0K (+100.0%) | 3.94% +3.940 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 40 | NORTHERN TRUST CORP | 283.1K +283.1K (+100.0%) | 665.4K +665.4K (+100.0%) | 3.79% +3.789 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 41 | IKARIAN CAPITAL, LLC | 275.0K +275.0K (+100.0%) | 646.2K +646.2K (+100.0%) | 3.68% +3.679 pp | 0.05% +0.050 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 42 | UBS GROUP AG | 247.8K +228.3K (+1,176.2%) | 582.2K +565.5K (+3,387.4%) | 3.31% +3.055 pp | 0.00% +0.000 pp | USD2.23 +5.4% | 7 qtrs — |
| 43 | QUADRATURE CAPITAL LTD | 240.6K +240.6K (+100.0%) | 565.4K +565.4K (+100.0%) | 3.22% +3.219 pp | 0.01% +0.006 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 44 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 212.7K +212.7K (+100.0%) | 499.7K +499.7K (+100.0%) | 2.85% +2.845 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 45 | SCIENTECH RESEARCH LLC | 211.4K +211.4K (+100.0%) | 496.9K +496.9K (+100.0%) | 2.83% +2.829 pp | 0.31% +0.313 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 46 | TD ASSET MANAGEMENT INC | 204.4K +204.4K (+100.0%) | 480.5K +480.5K (+100.0%) | 2.74% +2.736 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 47 | SPHERA FUNDS MANAGEMENT LTD. | 184.1K +184.1K (+100.0%) | 432.6K +432.6K (+100.0%) | 2.46% +2.463 pp | 0.08% +0.084 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 48 | DIADEMA PARTNERS LP | 166.0K +166.0K (+100.0%) | 390.2K +390.2K (+100.0%) | 2.22% +2.222 pp | 0.07% +0.067 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 49 | ACT CAPITAL MANAGEMENT, LLC | 150.0K +150.0K (+100.0%) | 352.5K +352.5K (+100.0%) | 2.01% +2.007 pp | 0.29% +0.285 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 50 | BOOTHBAY FUND MANAGEMENT, LLC | 132.6K +132.6K (+100.0%) | 311.7K +311.7K (+100.0%) | 1.77% +1.775 pp | 0.00% +0.005 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 51 | OMERS ADMINISTRATION CORP | 108.0K +108.0K (+100.0%) | 253.8K +253.8K (+100.0%) | 1.45% +1.445 pp | 0.00% +0.002 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 52 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 106.6K +106.6K (+100.0%) | 251.7K +251.7K (+100.0%) | 1.43% +1.427 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 53 | SILVERARC CAPITAL MANAGEMENT, LLC | 102.1K +102.1K (+100.0%) | 240.0K +240.0K (+100.0%) | 1.37% +1.366 pp | 0.03% +0.033 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 54 | PALE FIRE CAPITAL SE | 70.7K +70.7K (+100.0%) | 166.2K +166.2K (+100.0%) | 0.95% +0.946 pp | 0.01% +0.011 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 55 | BANK OF AMERICA CORP /DE/ | 70.1K +70.0K (+81,408.1%) | 164.7K +164.7K (+225,554.8%) | 0.94% +0.937 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 7 qtrs — |
| 56 | CITIGROUP INC | 52.3K +49.9K (+2,127.6%) | 122.9K +120.8K (+5,988.2%) | 0.70% +0.668 pp | 0.00% +0.000 pp | USD2.28 +3.1% | 2 qtrs — |
| 57 | JEFFERIES FINANCIAL GROUP INC. | 46.8K +46.8K (+100.0%) | 109.9K +109.9K (+100.0%) | 0.63% +0.626 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 58 | VIRTUS ETF ADVISERS LLC | 46.0K +46.0K (+100.0%) | 108.1K +108.1K (+100.0%) | 0.62% +0.616 pp | 0.05% +0.051 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 59 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 39.5K +39.5K (+100.0%) | 92.8K +92.8K (+100.0%) | 0.53% +0.528 pp | 0.00% +0.003 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 60 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 34.5K +34.5K (+100.0%) | 81.1K +81.1K (+100.0%) | 0.46% +0.462 pp | 0.02% +0.020 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 61 | TOTAL CLARITY WEALTH MANAGEMENT, INC. | 29.9K +29.9K (+100.0%) | 70.3K +70.3K (+100.0%) | 0.40% +0.401 pp | 0.02% +0.017 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 62 | TWO SIGMA INVESTMENTS, LP | 27.6K +27.6K (+100.0%) | 65.0K +65.0K (+100.0%) | 0.37% +0.370 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 63 | XTX TOPCO LTD | 21.7K +7.6K (+53.8%) | 50.9K +38.8K (+320.5%) | 0.29% +0.102 pp | 0.00% +0.001 pp | USD1.26 +86.5% | 3 qtrs — |
| 64 | VONTOBEL HOLDING LTD. | 20.0K +20.0K (+100.0%) | 47.0K +47.0K (+100.0%) | 0.27% +0.268 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 65 | COMMONWEALTH EQUITY SERVICES, LLC | 16.7K +16.7K (+100.0%) | 39.1K +39.1K (+100.0%) | 0.22% +0.223 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 66 | VICTORY CAPITAL MANAGEMENT INC | 16.1K +16.1K (+100.0%) | 37.8K +37.8K (+100.0%) | 0.22% +0.215 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 67 | LPL FINANCIAL LLC | 15.2K +15.2K (+100.0%) | 35.6K +35.6K (+100.0%) | 0.20% +0.203 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 68 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 15.0K +2.0K (+15.4%) | 35.3K +24.1K (+215.4%) | 0.20% +0.027 pp | 0.01% +0.004 pp | USD0.93 +152.7% | 3 qtrs — |
| 69 | WINTON GROUP LTD | 14.9K +14.9K (+100.0%) | 35.0K +35.0K (+100.0%) | 0.20% +0.199 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 70 | BARCLAYS PLC | 14.8K +14.8K (+100.0%) | 34.7K +34.7K (+100.0%) | 0.20% +0.198 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 71 | ATOM INVESTORS LP | 14.0K +14.0K (+100.0%) | 33.0K +33.0K (+100.0%) | 0.19% +0.188 pp | 0.00% +0.003 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 72 | BANK OF NEW YORK MELLON CORP | 12.9K +12.9K (+100.0%) | 30.3K +30.3K (+100.0%) | 0.17% +0.173 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 73 | VIRTU FINANCIAL LLC | 11.9K +11.9K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.16% +0.159 pp | 0.00% +0.001 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 74 | SCHONFELD STRATEGIC ADVISORS LLC | 11.2K +11.2K (+100.0%) | 26.4K +26.4K (+100.0%) | 0.15% +0.150 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 75 | CETERA INVESTMENT ADVISERS | 10.5K +10.5K (+100.0%) | 24.7K +24.7K (+100.0%) | 0.14% +0.141 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 76 | FNY INVESTMENT ADVISERS, LLC | 10.0K +10.0K (+100.0%) | 23.0K +23.0K (+100.0%) | 0.13% +0.133 pp | 0.01% +0.007 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 77 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.0K -4.4K (-81.0%) | 2.4K -2.2K (-48.1%) | 0.01% -0.059 pp | 0.00% 0.000 pp | USD2.18 +7.8% | 7 qtrs — |
| 78 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 500.00 +— (+0.0%) | 1.2K +745.0 (+173.3%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD0.86 +173.3% | 2 qtrs — |
| 79 | AVION WEALTH | 500.00 +500.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 80 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 100.00 +— (+0.0%) | 235.00 +149.0 (+173.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.30 -45.3% | 7 qtrs — |
| 81 | ADVISOR GROUP HOLDINGS, INC. | 66.00 +66.0 (+100.0%) | 155.00 +155.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.35 +0.0% | 1 qtrs NEW |
| 82 | WELLS FARGO & COMPANY/MN | 21.00 +— (+0.0%) | 49.00 +31.0 (+172.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.29 -45.2% | 7 qtrs — |
| 83 | FMR LLC | 10.00 +10.0 (+100.0%) | 24.00 +24.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.30 +2.2% | 1 qtrs NEW |
| 84 | TWO SIGMA SECURITIES, LLC | — -29.4K (-100.0%) | — -25.3K (-100.0%) | 0.00% -0.393 pp | 0.00% -0.004 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 38 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 1.10% | 851.3K | 2.82% |
| 2 | iShares Micro-Cap ETF IWC | 0.07% | 971.9K | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 219.1K | 0.20% |
| 4 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.17M | 0.24% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 298.8K | 0.30% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 29.3K | 0.25% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.01% | 134.7K | 0.08% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 5.1K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.01% | 7.46M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 48.7K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
4
Shares acquired
2.83M
Shares disposed
27.2K
Cash buys
2.00
Cash sales
2.00
Net activity
+2,802,115
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | Jones Mitchell Lawrence | Officer | S-Sale | D | Common Stock | 1,989 | 1.75 | 3.5K | 13,263 | D | ↗ |
| 2026-02-12 | Finley John David | Director / Officer | S-Sale | D | Common Stock | 3,896 | 1.75 | 6.8K | 27,353 | D | ↗ |
| 2026-02-11 | Jones Mitchell Lawrence | Officer | M-Exempt | D | Restricted Stock Units | 8,000 | 0.00 | — | 16,000 | D | ↗ |
| 2026-02-11 | Finley John David | Director / Officer | M-Exempt | A | Common Stock | 13,333 | 0.00 | — | 31,249 | D | ↗ |
| 2026-02-09 | Jones Mitchell Lawrence | Officer | A-Award | A | Restricted Stock Units | 787,000 | 0.00 | — | 787,000 | D | ↗ |
| 2026-02-09 | Finley John David | Director / Officer | A-Award | A | Restricted Stock Units | 2,011,000 | 0.00 | — | 2,011,000 | D | ↗ |
| 2026-01-16 | Williams Donald Allen | Director | P-Purchase | A | Common Stock | 5,000 | 1.67 | 8.4K | 10,728 | D | ↗ |
| 2026-01-09 | Williams Donald Allen | Director | P-Purchase | A | Common Stock | 5,000 | 1.88 | 9.4K | 5,728 | D | ↗ |
| 2025-10-06 | Williams Donald Allen | Director | A-Award | A | Restricted Stock Units | 182,000 | 0.00 | — | 182,000 | D | ↗ |
| 2025-10-06 | Wei Binxian | Director | A-Award | A | Restricted Stock Units | 60,600 | 0.00 | — | 60,600 | D | ↗ |
| 2025-10-06 | Jones Mitchell Lawrence | Officer | A-Award | A | Restricted Stock Units | 7,665,800 | 0.00 | — | 7,665,800 | D | ↗ |
| 2025-10-06 | Finley John David | Director / Officer | A-Award | A | Restricted Stock Units | 9,179,400 | 0.00 | — | 9,179,400 | D | ↗ |
| 2025-10-06 | Chuang Emil | Director | A-Award | A | Restricted Stock Units | 60,600 | 0.00 | — | 60,600 | D | ↗ |
| 2025-09-04 | Williams Donald Allen | Director | A-Award | A | Phantom Units | 64,400 | 0.00 | — | 64,400 | D | ↗ |
| 2025-09-04 | Wei Binxian | Director | A-Award | A | Phantom Units | 18,800 | 0.00 | — | 18,800 | D | ↗ |
| 2025-09-04 | Jones Mitchell Lawrence | Officer | A-Award | A | Phantom Units | 289,000 | 0.00 | — | 289,000 | D | ↗ |
| 2025-09-04 | Finley John David | Director / Officer | A-Award | A | Phantom Units | 323,400 | 0.00 | — | 323,400 | D | ↗ |
| 2025-09-04 | Chuang Emil | Director | A-Award | A | Phantom Units | 18,800 | 0.00 | — | 18,800 | D | ↗ |
| 2025-07-07 | Chuang Emil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-11 | Jones Mitchell Lawrence | Officer | A-Award | A | Stock Option (Right to Buy) | 29,000 | 1.13 | 32.8K | 29,000 | D | ↗ |
| 2025-02-11 | Finley John David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 47,000 | 1.13 | 53.1K | 47,000 | D | ↗ |
| 2024-11-21 | Williams Donald Allen | Director | M-Exempt | A | Comon Stock, par value $0.01 | 388 | 0.00 | — | 728 | D | ↗ |
| 2024-11-21 | Wei Binxian | Director | M-Exempt | A | Comon Stock, par value $0.01 | 388 | 0.00 | — | 855 | D | ↗ |
| 2024-07-11 | Williams Donald Allen | Director | A-Award | A | Common Stock Options | 2,100 | 4.49 | 9.4K | 2,100 | — | ↗ |
| 2024-07-11 | Wei Binxian | Director | A-Award | A | Common Stock Options | 2,100 | 4.49 | 9.4K | 2,100 | — | ↗ |
| 2024-07-11 | Fischbein Margery B. | Director | A-Award | A | Common Stock Options | 2,100 | 4.49 | 9.4K | 2,100 | — | ↗ |
| 2024-06-11 | Williams Donald Allen | Director | M-Exempt | A | Comon Stock, par value $0.01 | 340 | 0.00 | — | 340 | — | ↗ |
| 2024-06-11 | Wei Binxian | Director | M-Exempt | A | Comon Stock, par value $0.01 | 465 | 0.00 | — | 467 | — | ↗ |
| 2024-05-28 | Williams Donald Allen | Director | P-Purchase | A | Comon Stock, par value $0.01 | 1,000 | 4.86 | 4.9K | 1,000 | — | ↗ |
| 2024-05-28 | Jones Mitchell Lawrence | Officer | F-InKind | D | Common Stock, par value $0.01 | 810 | 4.76 | 3.9K | 2,758 | — | ↗ |
| 2024-05-28 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 467 | 4.76 | 2.2K | 9,592 | — | ↗ |
| 2024-05-24 | Finley John David | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 | 1,000 | 4.81 | 4.8K | 8,437 | — | ↗ |
| 2024-05-20 | Finley John David | Director / Officer | A-Award | A | Common Stock, par value $0.01 | 666 | 4.97 | 3.3K | 7,437 | — | ↗ |
| 2024-05-07 | Fischbein Margery B. | Director | — | D | Common Stock Purchase Option | 1,000 | 7.90 | 7.9K | 0 | — | ↗ |
| 2024-05-06 | Jones Mitchell Lawrence | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 90 | 8.46 | 761.40 | 724 | — | ↗ |
| 2024-05-06 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 232 | 0.00 | — | 1,622 | — | ↗ |
| 2024-03-11 | Finley John David | Director / Officer | M-Exempt | A | Common Stock, par value $0.01 | 5,558 | 0.00 | — | 96,849 | — | ↗ |
| 2024-02-09 | Neal James R | Director | M-Exempt | A | Common Stock, par value $0.01 | 5,100 | 0.00 | — | 5,100 | — | ↗ |
| 2024-02-08 | Trenschel Robert J. | Director | M-Exempt | D | Common Stock Options | 12,160 | 1.60 | 19.5K | 0 | — | ↗ |
| 2024-02-08 | Diaz Stephanie | Director | M-Exempt | A | Common Stock, par value $0.01 | 6,980 | 0.00 | — | 6,980 | — | ↗ |
| 2024-02-08 | Csimma Cristina | Director | M-Exempt | D | Common Stock Options | 9,580 | 1.60 | 15.3K | 0 | — | ↗ |
| 2024-02-06 | Jones Mitchell Lawrence | Officer | M-Exempt | A | Common Stock, par value $0.01 | 4,558 | 0.00 | — | 7,482 | — | ↗ |
| 2024-02-06 | Finley John David | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 | 10,000 | 0.47 | 4.7K | 84,649 | — | ↗ |
| 2024-01-31 | Williams Donald Allen | Director | P-Purchase | A | Common Stock, par value $0.01 | 10,000 | 0.61 | 6.1K | 30,000 | — | ↗ |
| 2024-01-31 | Finley John David | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 | 10,000 | 0.56 | 5.6K | 74,649 | — | ↗ |
| 2024-01-03 | Finley John David | Director / Officer | M-Exempt | A | Common Stock, par value $0.01 | 1,309 | 0.00 | — | 64,649 | — | ↗ |
| 2023-12-11 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,559 | 0.00 | — | 55,583 | — | ↗ |
| 2023-11-21 | Williams Donald Allen | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-21 | Wei Binxian | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-21 | Trenschel Robert J. | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-21 | Neal James R | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-21 | Jones Mitchell Lawrence | Officer | A-Award | A | Restricted Stock Units | 28,000 | 0.00 | — | 28,000 | — | ↗ |
| 2023-11-21 | GRAY MARY ANN | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-21 | Finley John David | Director / Officer | A-Award | A | Restricted Stock Units | 38,000 | 0.00 | — | 38,000 | — | ↗ |
| 2023-11-21 | Diaz Stephanie | Director | A-Award | A | Common Stock Options | 6,880 | 0.59 | 4.1K | 6,880 | — | ↗ |
| 2023-11-21 | Csimma Cristina | Director | A-Award | A | Restricted Stock Units | 5,820 | 0.00 | — | 5,820 | — | ↗ |
| 2023-11-20 | Finley John David | Director / Officer | A-Award | A | Common Stock, par value $0.01 | 10,000 | 0.51 | 5.1K | 57,781 | — | ↗ |
| 2023-11-07 | Jones Mitchell Lawrence | Officer | F-InKind | D | Common Stock, par value $0.01 | 1,630 | 0.54 | 878.41 | 2,926 | — | ↗ |
| 2023-11-06 | Jones Mitchell Lawrence | Officer | M-Exempt | D | Restricted Stock Units | 4,556 | 0.00 | — | 50,144 | — | ↗ |
| 2023-11-06 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,475 | 0.00 | — | 31,275 | — | ↗ |
| 2023-10-04 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 397 | 0.55 | 218.39 | 44,306 | — | ↗ |
| 2023-10-03 | Finley John David | Director / Officer | M-Exempt | A | Common Stock, par value $0.01 | 1,309 | 0.00 | — | 44,703 | — | ↗ |
| 2023-09-27 | Williams Donald Allen | Director | P-Purchase | A | Common Stock, par value $0.01 | 20,000 | 0.54 | 10.8K | 20,000 | — | ↗ |
| 2023-09-27 | Finley John David | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 | 15,000 | 0.54 | 8.1K | 43,394 | — | ↗ |
| 2023-09-14 | Trenschel Robert J. | Director | S-Sale | D | Common Stock, par value $0.01 | 300 | 0.64 | 192.00 | 0 | — | ↗ |
| 2023-09-13 | Finley John David | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 | 15,000 | 0.66 | 9.8K | 28,394 | — | ↗ |
| 2023-09-12 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 1,792 | 0.66 | 1.2K | 13,394 | — | ↗ |
| 2023-09-11 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,558 | 0.00 | — | 61,142 | — | ↗ |
| 2023-09-05 | Jones Mitchell Lawrence | Officer | — | D | Common Stock Purchase Option | 75,000 | 0.69 | 51.7K | 0 | — | ↗ |
| 2023-08-11 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 1,040 | 0.70 | 728.00 | 9,628 | — | ↗ |
| 2023-08-06 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,475 | 0.00 | — | 34,750 | — | ↗ |
| 2023-07-06 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 389 | 1.76 | 686.20 | 7,193 | — | ↗ |
| 2023-07-03 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 1,309 | 0.00 | — | 2,618 | — | ↗ |
| 2023-06-13 | Finley John David | Director / Officer | F-InKind | D | Common Stock, par value $0.01 | 1,050 | 1.54 | 1.6K | 6,273 | — | ↗ |
| 2023-06-12 | Finley John David | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,475 | 0.00 | — | 38,225 | — | ↗ |
| 2023-06-11 | Williams Donald Allen | Director | A-Award | A | Common Stock Options | 12,160 | 1.60 | 19.5K | 12,160 | — | ↗ |
| 2023-06-11 | Wei Binxian | Director | A-Award | A | Restricted Stock Units | 6,980 | 0.00 | — | 6,980 | — | ↗ |
| 2023-06-11 | Trenschel Robert J. | Director | A-Award | A | Restricted Stock Units | 5,100 | 0.00 | — | 5,100 | — | ↗ |
| 2023-06-11 | Neal James R | Director | A-Award | A | Common Stock Options | 12,160 | 1.60 | 19.5K | 12,160 | — | ↗ |
| 2023-06-11 | GRAY MARY ANN | Director | A-Award | A | Common Stock Options | 12,160 | 1.60 | 19.5K | 12,160 | — | ↗ |
| 2023-06-11 | Finley John David | Director / Officer | A-Award | A | Common Stock Options | 148,500 | 1.60 | 237.6K | 148,500 | — | ↗ |
| 2023-06-11 | Diaz Stephanie | Director | A-Award | A | Restricted Stock Units | 6,980 | 0.00 | — | 6,980 | — | ↗ |
| 2023-06-11 | Csimma Cristina | Director | A-Award | A | Restricted Stock Units | 6,980 | 0.00 | — | 6,980 | — | ↗ |
| 2023-04-03 | McRae Robert Curtis | Officer | M-Exempt | D | Restricted Stock Units | 655 | 0.00 | — | 1,963 | — | ↗ |
| 2023-04-03 | Finley John David | Director / Officer | M-Exempt | A | Common Stock, par value $0.01 | 1,309 | 0.00 | — | 4,283 | — | ↗ |
| 2023-02-06 | McRae Robert Curtis | Officer | — | D | Common Stock Purchase Option | 12,000 | 2.40 | 28.8K | 0 | — | ↗ |
| 2023-02-06 | Finley John David | Director / Officer | A-Award | A | Restricted Performance Stock Units | 32,500 | 0.00 | — | 32,500 | — | ↗ |
| 2023-02-02 | McRae Robert Curtis | Officer | — | D | Common Stock | 0 | 0.00 | — | 240 | — | ↗ |
| 2023-01-03 | Finley John David | Officer | A-Award | A | Restricted Stock Units | 5,236 | 0.00 | — | 5,236 | — | ↗ |
| 2022-09-01 | Finley John David | Officer | P-Purchase | A | Common Stock, par value $0.01 | 19,481 | 0.14 | 2.8K | 148,727 | — | ↗ |
| 2022-08-23 | Finley John David | Officer | P-Purchase | A | Common Stock, par value $0.01 | 7,350 | 0.16 | 1.2K | 129,246 | — | ↗ |
| 2022-08-16 | McRae Robert Curtis | Officer | — | D | Series 2 Common Stock Purchase Warrant | 240 | 2.38 | 571.20 | 0 | — | ↗ |
| 2022-08-16 | Hallam Thomas | Officer | P-Purchase | A | Series 2 Common Stock Purchase Warrant | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-08-16 | Finley John David | Officer | P-Purchase | A | Series 2 Common Stock Purchase Warrant | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-04-29 | Finley John David | Officer | J-Other | A | Common Stock | 12,545 | 0.00 | — | 38,867 | — | ↗ |
| 2022-03-29 | Dawson Michael John | Officer | P-Purchase | A | Common Stock | 15,000 | 1.14 | 17.1K | 15,000 | — | ↗ |
| 2022-03-28 | Hallam Thomas | Officer | P-Purchase | A | Common Stock | 10,000 | 1.18 | 11.8K | 17,592 | — | ↗ |
| 2022-03-24 | Finley John David | Officer | P-Purchase | A | Common Stock | 7,500 | 1.09 | 8.2K | 21,896 | — | ↗ |
| 2022-02-17 | Hallam Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 156,600 | 0.95 | 148.8K | 156,600 | — | ↗ |
| 2022-02-17 | Finley John David | Officer | A-Award | A | Stock Option (right to buy) | 64,800 | 0.95 | 61.6K | 64,800 | — | ↗ |
| 2022-02-17 | Dawson Michael John | Officer | A-Award | A | Stock Option (right to buy) | 32,400 | 0.95 | 30.8K | 32,400 | — | ↗ |
| 2022-02-09 | McRae Robert Curtis | Officer | — | D | Common Stock Purchase Option | 1,800 | 52.50 | 94.5K | 0 | — | ↗ |
| 2021-11-18 | Williams Donald Allen | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Wei Binxian | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Trenschel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Neal James R | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Hallam Thomas | Director / Officer | A-Award | A | Stock Option (right to buy) | 267,868 | 2.32 | 621.5K | 267,868 | — | ↗ |
| 2021-11-18 | GRAY MARY ANN | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Finley John David | Officer | A-Award | A | Stock Option (right to buy) | 178,091 | 2.32 | 413.2K | 178,091 | — | ↗ |
| 2021-11-18 | Diaz Stephanie | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-11-18 | Dawson Michael John | Officer | A-Award | A | Stock Option (right to buy) | 39,294 | 2.32 | 91.2K | 39,294 | — | ↗ |
| 2021-11-18 | Csimma Cristina | Director | A-Award | A | Stock Option (right to buy) | 48,340 | 2.32 | 112.1K | 48,340 | — | ↗ |
| 2021-09-21 | Hallam Thomas | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 2.49 | 14.9K | 7,592 | — | ↗ |
| 2021-09-21 | Finley John David | Officer | P-Purchase | A | Common Stock | 2,000 | 2.44 | 4.9K | 14,396 | — | ↗ |
| 2021-09-10 | Trenschel Robert J. | Director | P-Purchase | A | Common Stock | 2,142 | 2.98 | 6.4K | 14,999 | — | ↗ |
| 2021-09-09 | Trenschel Robert J. | Director | P-Purchase | A | Common Stock | 3,400 | 2.89 | 9.8K | 12,857 | — | ↗ |
| 2021-09-08 | Trenschel Robert J. | Director | P-Purchase | A | Common Stock | 5,000 | 2.75 | 13.8K | 9,457 | — | ↗ |
| 2021-09-07 | Trenschel Robert J. | Director | P-Purchase | A | Common Stock | 2,707 | 2.78 | 7.5K | 4,457 | — | ↗ |
| 2021-08-31 | Trenschel Robert J. | Director | P-Purchase | A | Common Stock | 1,750 | 2.75 | 4.8K | 1,750 | — | ↗ |
| 2021-08-27 | Finley John David | Officer | P-Purchase | A | Common Stock | 8,400 | 2.65 | 22.3K | 12,396 | — | ↗ |
| 2021-08-19 | Yuma Regional Medical Center | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,814,375 | — | ↗ |
| 2021-04-27 | Williams Donald Allen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-27 | Trenschel Robert J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-27 | Neal James R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-27 | Hallam Thomas | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-27 | Finley John David | Officer | A-Award | A | Warrant (Right to Buy) | 49 | 41.20 | 2.0K | 49 | — | ↗ |
| 2021-04-27 | Diaz Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 10,203 | 41.20 | 420.4K | 10,203 | — | ↗ |
| 2021-04-27 | Dawson Michael John | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-01 | Wei Binxian | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2021-04-01 | Mazzo David J | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2021-04-01 | GRAY MARY ANN | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2021-04-01 | Csimma Cristina | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2020-10-15 | Yuma Regional Medical Center | 10% Owner | — | D | Warrant to Purchase Common Stock (right to purchase) | 1,223 | 26.85 | 32.8K | 0 | — | ↗ |
| 2020-04-03 | Wei Binxian | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2020-04-03 | Mazzo David J | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2020-04-03 | GRAY MARY ANN | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2020-04-03 | Csimma Cristina | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2019-08-15 | Yuma Regional Medical Center | 10% Owner | — | D | Warrant to Purchase Common Stock (right to purchase) | 13,595 | 41.20 | 560.1K | 0 | — | ↗ |
| 2019-07-19 | GRAY MARY ANN | Director | — | D | Common Stock | 0 | 0.00 | — | 7,355 | — | ↗ |
| 2019-07-01 | Wei Binxian | Director | — | D | Common Stock Purchase Option | 187,510 | 0.30 | 56.3K | 0 | — | ↗ |
| 2019-07-01 | SMITH SANDFORD D | Director | A-Award | A | Common Stock | 166,667 | 0.00 | — | 219,916 | — | ↗ |
| 2019-07-01 | OLDAKER WILLIAM CLYDE | Director | A-Award | A | Common Stock Purchase Option | 187,510 | 0.30 | 56.3K | 187,510 | — | ↗ |
| 2019-07-01 | OGILVIE SCOTT VARDE | Director | A-Award | A | Common Stock Purchase Option | 187,510 | 0.30 | 56.3K | 187,510 | — | ↗ |
| 2019-07-01 | Mazzo David J | Director | A-Award | A | Common Stock Purchase Option | 187,510 | 0.30 | 56.3K | 187,510 | — | ↗ |
| 2019-07-01 | Csimma Cristina | Director | A-Award | A | Common Stock Purchase Option | 187,510 | 0.30 | 56.3K | 187,510 | — | ↗ |
| 2019-06-17 | Mazzo David J | Director | — | D | Common Stock Purchase Option | 9,091 | 0.36 | 3.3K | 0 | — | ↗ |
| 2019-02-10 | Wei Binxian | Director | — | D | Common Stock Purchase Option | 118,497 | 0.44 | 52.1K | 0 | — | ↗ |
| 2019-01-01 | Carter Kenneth C | Director / Officer | — | D | Common Stock Purchase Option | 156,213 | 8.50 | 1.33M | 0 | — | ↗ |
| 2018-07-02 | WESTREICH STANLEY | Director | A-Award | A | Common Stock Purchase Option | 59,660 | 1.11 | 66.2K | 59,660 | — | ↗ |
| 2018-07-02 | SMITH SANDFORD D | Director | A-Award | A | Common Stock | 45,046 | 0.00 | — | 50,899 | — | ↗ |
| 2018-07-02 | OLDAKER WILLIAM CLYDE | Director | A-Award | A | Common Stock Purchase Option | 59,660 | 1.11 | 66.2K | 59,660 | — | ↗ |
| 2018-07-02 | OGILVIE SCOTT VARDE | Director | A-Award | A | Common Stock Purchase Option | 59,660 | 1.11 | 66.2K | 59,660 | — | ↗ |
| 2018-07-02 | Csimma Cristina | Director | A-Award | A | Common Stock Purchase Option | 59,660 | 1.11 | 66.2K | 59,660 | — | ↗ |
| 2017-11-07 | Daly Richard J | Director / Officer | A-Award | A | Common Stock Purchase Option | 100,000 | 1.12 | 112.0K | 100,000 | — | ↗ |
| 2017-09-25 | Csimma Cristina | Director | — | D | Common Stock | 0 | 0.00 | — | 28,598 | — | ↗ |
| 2017-07-14 | WESTREICH STANLEY | Director | A-Award | A | Common Stock | 18,622 | 0.00 | — | 143,281 | — | ↗ |
| 2017-07-14 | SMITH SANDFORD D | Director | A-Award | A | Restricted Stock Units | 9,311 | 0.00 | — | 9,311 | — | ↗ |
| 2017-07-14 | OLDAKER WILLIAM CLYDE | Director | A-Award | A | Common Stock | 18,622 | 0.00 | — | 33,763 | — | ↗ |
| 2017-07-14 | OGILVIE SCOTT VARDE | Director | A-Award | A | Common Stock Purchase Option | 13,574 | 5.37 | 72.9K | 13,574 | — | ↗ |
| 2017-05-17 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 7,500 | 4.00 | 30.0K | 23,312 | — | ↗ |
| 2017-04-11 | WESTREICH STANLEY | Director | A-Award | A | Common Stock Purchase Option | 33,408 | 4.96 | 165.7K | 33,408 | — | ↗ |
| 2017-03-24 | LLOYD JONES JONATHAN BRIAN | Officer | P-Purchase | A | Common Stock | 5,455 | 5.50 | 30.0K | 7,859 | — | ↗ |
| 2017-02-24 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 2,591 | 3.86 | 10.0K | 15,812 | — | ↗ |
| 2017-01-25 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 2,841 | 3.52 | 10.0K | 13,221 | — | ↗ |
| 2016-12-23 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 32,259 | 0.31 | 10.0K | 134,939 | — | ↗ |
| 2016-11-25 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 35,715 | 0.28 | 10.0K | 102,680 | — | ↗ |
| 2016-10-25 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 35,715 | 0.28 | 10.0K | 66,965 | — | ↗ |
| 2016-09-23 | LLOYD JONES JONATHAN BRIAN | Officer | P-Purchase | A | Common Stock | 31,250 | 0.32 | 10.0K | 31,250 | — | ↗ |
| 2016-09-23 | Daly Richard J | Director / Officer | P-Purchase | A | Common Stock | 31,250 | 0.32 | 10.0K | 31,250 | — | ↗ |
| 2016-03-08 | LLOYD JONES JONATHAN BRIAN | Officer | A-Award | A | Common Stock Purchase Option | 79,776 | 0.94 | 75.0K | 79,776 | — | ↗ |
| 2016-02-15 | Daly Richard J | Director / Officer | — | D | Common Stock Purchase Option | 2,750,000 | 0.69 | 1.90M | 0 | — | ↗ |
| 2016-01-27 | GARR RICHARD | Director / Officer | M-Exempt | A | Common Stock | 19,802 | 0.00 | — | 1,456,269 | — | ↗ |
| 2015-11-19 | OLDAKER WILLIAM CLYDE | Director | M-Exempt | D | Restricted Stock Unit | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2015-11-19 | JOHE KARL | Director / Officer | M-Exempt | A | Common Stock | 143,247 | 0.00 | — | 969,551 | — | ↗ |
| 2015-11-19 | GARR RICHARD | Director / Officer | M-Exempt | A | Common Stock | 138,122 | 0.00 | — | 1,474,243 | — | ↗ |
| 2015-11-16 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.09 | 27.3K | 826,304 | — | ↗ |
| 2015-11-09 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.18 | 29.5K | 851,304 | — | ↗ |
| 2015-11-02 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.17 | 29.4K | 876,304 | — | ↗ |
| 2015-11-02 | GARR RICHARD | Director / Officer | G-Gift | D | Common Stock | 33,477 | 0.00 | — | 1,369,597 | — | ↗ |
| 2015-10-26 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.13 | 28.2K | 901,304 | — | ↗ |
| 2015-10-19 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.23 | 30.7K | 926,304 | — | ↗ |
| 2015-10-12 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.31 | 32.7K | 951,304 | — | ↗ |
| 2015-10-05 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.26 | 31.5K | 976,304 | — | ↗ |
| 2015-09-28 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.64 | 41.0K | 1,001,304 | — | ↗ |
| 2015-09-24 | GARR RICHARD | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 1,453,074 | — | ↗ |
| 2015-09-21 | JOHE KARL | Director / Officer | S-Sale | D | Common Stock | 25,000 | 1.52 | 38.1K | 1,026,304 | — | ↗ |
| 2015-08-13 | JOHE KARL | Director / Officer | J-Other | D | Common Stock | 16,627 | 0.00 | — | 1,051,304 | — | ↗ |
| 2015-07-24 | GARR RICHARD | Director / Officer | F-InKind | D | Common Stock | 380,263 | 1.93 | 733.9K | 1,503,074 | — | ↗ |
| 2015-07-22 | JOHE KARL | Director / Officer | M-Exempt | A | Common Stock | 1,200,000 | 0.50 | 600.0K | 1,688,947 | — | ↗ |
| 2015-07-01 | WESTREICH STANLEY | Director | A-Award | A | Common Stock | 106,952 | 0.00 | — | 1,564,854 | — | ↗ |
| 2015-07-01 | Sohn Catherine A. | Director | A-Award | A | Common Stock | 106,952 | 0.00 | — | 106,952 | — | ↗ |
| 2015-07-01 | SMITH SANDFORD D | Director | A-Award | A | Common Stock | 106,952 | 0.00 | — | 106,952 | — | ↗ |
| 2015-07-01 | OLDAKER WILLIAM CLYDE | Director | A-Award | A | Common Stock | 53,476 | 0.00 | — | 181,826 | — | ↗ |
| 2015-07-01 | OGILVIE SCOTT VARDE | Director | A-Award | A | Common Stock Purchase Option | 99,824 | 1.87 | 186.7K | 99,824 | — | ↗ |
| 2015-05-27 | OLDAKER WILLIAM CLYDE | Director | M-Exempt | A | Common Stock | 60,000 | 1.32 | 79.2K | 176,939 | — | ↗ |
| 2015-05-22 | OGILVIE SCOTT VARDE | Director | M-Exempt | A | Common Stock | 60,000 | 1.32 | 79.2K | 80,837 | — | ↗ |
| 2015-05-18 | LLOYD JONES JONATHAN BRIAN | Officer | — | D | Common Stock Purchase Option | 50,000 | 1.71 | 85.5K | 0 | — | ↗ |
| 2015-04-17 | JOHE KARL | Director / Officer | G-Gift | D | Common Stock | 6,800 | 0.00 | — | 488,947 | — | ↗ |
| 2015-03-03 | GARR RICHARD | Director / Officer | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 235,000 | — | ↗ |
| 2015-02-20 | JOHE KARL | Director / Officer | A-Award | A | Common Stock Purchase Option | 315,126 | 3.80 | 1.20M | 315,126 | — | ↗ |
Executive team
Top executives
Shares Outstanding
167.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | J.D. Finley Chief Executive Officer and Chief Financial Officer | 575.0K | — | 17.74M | 47.4K | 431.3K | — | 18.79M | 94.64% | ↗ |
| 2 | 2025 | Mitchell Jones, M.D., Ph.D. President and Chief Medical Officer | 440.0K | — | 14.81M | 29.2K | 264.0K | — | 15.55M | 95.47% | ↗ |
| 3 | 2024 | J.D. Finley Chief Executive Officer and Chief Financial Officer | 542.0K | — | — | — | 271.0K | — | 813.0K | 0.00% | ↗ |
| 4 | 2024 | Mitchell Jones, M.D., Ph.D. Chief Medical Officer | 415.0K | — | — | — | 166.0K | — | 581.0K | 0.00% | ↗ |
| 5 | 2024 | Mitchell Jones, M.D., Ph.D. President and Chief Medical Officer | 415.0K | — | — | — | 166.0K | — | 581.0K | 0.00% | ↗ |
| 6 | 2023 | J.D. Finley Chief Executive Officer and Chief Financial Officer | 520.3K | — | 264.5K | 221.2K | 271.0K | — | 1.28M | 38.04% | ↗ |
| 7 | 2023 | Mitchell Jones, M.D., Ph.D. Chief Medical Officer | 135.2K | — | 54.2K | 49.6K | 166.0K | 53.0K | 458.0K | 22.66% | ↗ |
| 8 | 2023 | Robert McRae Chief Operating Officer | 145.8K | — | 24.9K | 739.00 | — | 28.0K | 199.4K | 12.83% | ↗ |
| 9 | 2022 | J.D. Finley Chief Executive Officer and Chief Financial Officer | 440.5K | — | — | 40.0K | 133.1K | — | 613.6K | 6.51% | ↗ |
| 10 | 2022 | Thomas Hallam, Ph.D. Former Chief Executive Officer | 415.2K | — | — | 96.6K | — | 22.1K | 533.8K | 18.09% | ↗ |
| 11 | 2022 | Robert McRae Chief Operating Officer | 350.0K | — | — | 61.1K | 89.4K | — | 500.5K | 12.20% | ↗ |
| 12 | 2022 | Michael Dawson Former Chief Medical Officer | 94.5K | — | — | 20.0K | — | 74.7K | 189.2K | 10.56% | ↗ |
| 13 | 2022 | Herbert Slade, MD, FAAAAI Chief Medical Officer | — | — | — | — | — | 59.1K | 59.1K | 0.00% | ↗ |
| 14 | 2021 | Kenneth Carter Executive Chairman | 133.9K | — | — | — | — | 1.33M | 1.46M | 0.00% | ↗ |
| 15 | 2021 | Thomas Hallam, Ph.D. Chief Executive Officer | 453.6K | 30.0K | — | 750.5K | 159.0K | 1.8K | 1.39M | 53.80% | ↗ |
| 16 | 2021 | Thomas Hallam, Ph.D. Former Chief Executive Officer | 453.6K | 30.0K | — | 750.5K | 159.0K | 1.8K | 1.39M | 53.80% | ↗ |
| 17 | 2021 | Matthew Kalnik President and Chief Operating Officer of Seneca | 105.9K | — | — | — | — | 1.23M | 1.33M | 0.00% | ↗ |
| 18 | 2021 | J.D. Finley Chief Financial Officer | 365.4K | 50.0K | — | 593.3K | 104.0K | — | 1.11M | 53.32% | ↗ |
| 19 | 2021 | J.D. Finley Chief Executive Officer and Chief Financial Officer | 365.4K | 50.0K | — | 593.3K | 104.0K | — | 1.11M | 53.32% | ↗ |
| 20 | 2021 | Dane Saglio Chief Financial Officer of Seneca | 81.3K | — | — | — | — | 915.8K | 997.1K | 0.00% | ↗ |
| 21 | 2021 | Michael Dawson Chief Medical Officer | 111.7K | — | — | 96.0K | 27.8K | — | 235.6K | 40.77% | ↗ |
| 22 | 2021 | Michael Dawson Former Chief Medical Officer | 111.7K | — | — | 96.0K | 27.8K | — | 235.6K | 40.77% | ↗ |
| 23 | 2021 | Robert McRae Chief Operating Officer | 12.2K | 50.0K | — | — | — | — | 62.2K | 0.00% | ↗ |
| 24 | 2020 | Kenneth Carter, Executive Chairman | 492.5K | — | — | 409.9K | — | — | 902.4K | 45.42% | ↗ |
| 25 | 2020 | Kenneth Carter Executive Chairman | 492.5K | — | — | 409.9K | — | — | 902.4K | 45.42% | ↗ |
| 26 | 2020 | Matthew Kalnik President and Chief Operating Officer of Seneca | 311.3K | — | — | 340.2K | — | 171.1K | 822.6K | 41.36% | ↗ |
| 27 | 2020 | Matthew Kalnik, PhD Chief Operating Officer and President | 311.3K | — | — | 340.2K | — | 171.1K | 822.6K | 41.36% | ↗ |
| 28 | 2020 | Thomas Hallam, Ph.D. Chief Executive Officer | 377.0K | 16.6K | — | 226.1K | 146.1K | 3.3K | 769.0K | 29.40% | ↗ |
| 29 | 2020 | J.D. Finley Chief Financial Officer | 292.5K | 13.5K | — | 146.3K | 78.8K | 660.00 | 531.7K | 27.50% | ↗ |
| 30 | 2020 | Dane Saglio Chief Financial Officer | 281.3K | — | — | 85.1K | — | 154.5K | 520.8K | 16.33% | ↗ |
| 31 | 2020 | Dane Saglio Chief Financial Officer of Seneca | 281.3K | — | — | 85.1K | — | 154.5K | 520.8K | 16.33% | ↗ |
| 32 | 2020 | Michael Dawson Chief Medical Officer | 110.5K | 6.0K | — | 51.5K | 15.4K | — | 183.3K | 28.10% | ↗ |
| 33 | 2019 | Kenneth Carter, PhD, Executive Chairman | 395.0K | 20.0K | — | 425.4K | — | — | 840.4K | 50.62% | ↗ |
| 34 | 2019 | Kenneth Carter, Executive Chairman | 395.0K | 20.0K | — | 425.4K | — | — | 840.4K | 50.62% | ↗ |
| 35 | 2019 | Matthew Kalnik, PhD Chief Operating Officer and President | — | — | — | — | — | 358.8K | 358.8K | 0.00% | ↗ |
| 36 | 2019 | Dane Saglio Chief Financial Officer | — | — | — | — | — | 84.8K | 84.00 | 0.00% | ↗ |
| 37 | 2018 | James Scully Chief Executive, President | 208.7K | — | — | 191.3K | — | — | 400.0K | 47.82% | ↗ |
| 38 | 2018 | James Scully, Former Chief Executive, President | 208.7K | — | — | 191.3K | — | — | 400.0K | 47.82% | ↗ |
| 39 | 2018 | Richard J. Daly Former Chief Executive, President | 239.2K | 146.4K | — | — | — | — | 385.5K | 0.00% | ↗ |
| 40 | 2018 | Richard J. Daly, Former Chief Executive, President | 239.2K | 146.4K | — | — | — | — | 385.5K | 0.00% | ↗ |
| 41 | 2017 | Richard J. Daly Chief Executive, President | 410.0K | — | — | 85.4K | — | — | 495.4K | 17.25% | ↗ |
| 42 | 2017 | Richard J. Daly Former Chief Executive, President | 410.0K | — | — | 85.4K | — | — | 495.4K | 17.25% | ↗ |
| 43 | 2017 | Jonathan Lloyd Jones Former Chief Financial Officer | 315.0K | — | — | — | — | — | 315.0K | 0.00% | ↗ |
| 44 | 2017 | Jonathan Lloyd Jones Chief Financial Officer | 315.0K | — | — | — | — | — | 315.0K | 0.00% | ↗ |
| 45 | 2016 | Richard J. Daly Chief Executive, President | 367.8K | — | 183.9K | 1.21M | — | — | 1.76M | 79.10% | ↗ |
| 46 | 2016 | Richard J. Daly Chief Executive Officer | 367.8K | 183.9K | — | 1.21M | — | — | 1.76M | 68.65% | ↗ |
| 47 | 2016 | Karl Johe Chief Scientific Officer | 598.3K | 359.0K | — | — | — | 6.0K | 963.3K | 0.00% | ↗ |
| 48 | 2016 | I. Richard Garr Former CEO, President, General Counsel ("PEO") | 73.3K | — | — | — | — | 544.7K | 631.3K | 0.00% | ↗ |
| 49 | 2016 | Jonathan Lloyd Jones Former Chief Financial Officer | 315.0K | 157.5K | — | 49.0K | — | — | 521.5K | 9.39% | ↗ |
| 50 | 2016 | Jonathan Lloyd Jones Chief Financial Officer | 315.0K | 157.5K | — | 49.0K | — | — | 521.5K | 9.39% | ↗ |
| 51 | 2015 | Karl Johe Chief Scientific Officer | 750.0K | 112.5K | — | — | — | 6.0K | 868.5K | 0.00% | ↗ |
| 52 | 2015 | I. Richard Garr Former CEO, President, General Counsel ("PEO") | 434.5K | — | — | — | — | 6.0K | 440.5K | 0.00% | ↗ |
| 53 | 2015 | I. Richard Garr Chief Executive, President, General Counsel (“PEO”) | 434.5K | — | — | — | — | 6.0K | 440.5K | 0.00% | ↗ |
| 54 | 2015 | Jonathan Lloyd Jones Chief Financial Officer | 195.9K | 49.0K | — | 49.0K | — | 78.9K | 372.7K | 13.14% | ↗ |
| 55 | 2015 | Jonathan Lloyd Jones Former Chief Financial Officer | 195.9K | 32.7K | — | 53.9K | — | 25.0K | 307.4K | 17.52% | ↗ |
| 56 | 2014 | Karl Johe, Ph.D . Chief Scientific Officer | 750.0K | 450.0K | — | 1.15M | — | 6.0K | 2.36M | 48.90% | ↗ |
| 57 | 2014 | Karl Johe Chief Scientific Officer | 750.0K | 450.0K | — | 1.15M | — | 6.0K | 2.36M | 48.90% | ↗ |
| 58 | 2014 | I. Richard Garr Chief Executive, President, General Counsel (“PEO”) | 407.0K | 244.2K | — | 407.0K | — | 6.0K | 1.06M | 38.24% | ↗ |
| 59 | 2014 | I. Richard Garr Chief Executive, President, General Counsel ("PEO") | 407.0K | 244.2K | — | 407.0K | — | 6.0K | 1.06M | 38.24% | ↗ |
| 60 | 2013 | Karl Johe, Ph.D . Chief Scientific Officer | 422.1K | 253.3K | — | 2.28M | — | 6.0K | 2.97M | 77.02% | ↗ |
| 61 | 2013 | Karl Johe Chief Scientific Officer | 422.1K | 253.3K | — | 2.28M | — | 6.0K | 2.97M | 77.02% | ↗ |
| 62 | 2013 | I. Richard Garr Chief Executive, President, General Counsel ("PEO") | 407.0K | 244.2K | — | 407.0K | — | 6.0K | 1.06M | 38.24% | ↗ |
| 63 | 2013 | I. Richard Garr Chief Executive, President, General Counsel (“PEO”) | 407.0K | 244.2K | — | 407.0K | — | 6.0K | 1.06M | 38.24% | ↗ |
| 64 | 2012 | Chief Scientific Officer | 422.1K | 253.3K | — | — | — | 6.0K | 2.50M | 0.00% | ↗ |
| 65 | 2012 | Karl Johe Chief Scientific | 422.1K | 253.3K | — | 1.82M | — | 6.0K | 2.50M | 72.76% | ↗ |
| 66 | 2012 | I. Richard Garr Chief Executive, President, General Counsel ("PEO") | 407.0K | 195.4K | — | 407.0K | — | 6.0K | 1.02M | 40.08% | ↗ |
| 67 | 2012 | Thomas Hazel Senior Vice | 225.0K | 56.3K | — | — | — | — | 281.3K | 0.00% | ↗ |
| 68 | 2011 | Karl Johe Chief Scientific | 422.1K | 253.3K | — | 422.1K | — | 6.0K | 1.10M | 38.25% | ↗ |
| 69 | 2011 | Karl Johe Chief Scientific Officer | 422.1K | 253.3K | — | — | — | 6.0K | 1.10M | 0.00% | ↗ |
| 70 | 2011 | I. Richard Garr Chief Executive, President, General Counsel ("PEO") | 407.0K | 73.3K | — | 512.8K | — | 6.0K | 999.1K | 51.33% | ↗ |
| 71 | 2011 | I. Richard Garr Chief Executive President, General Counsel (“PEO”) | 407.0K | 73.3K | — | 512.8K | — | 6.0K | 999.1K | 51.33% | ↗ |
| 72 | 2011 | John Conron Chief Financial Officer | 225.0K | — | — | — | — | 6.0K | 231.0K | 0.00% | ↗ |
| 73 | 2011 | Thomas Hazel Senior Vice President of Research | 206.3K | 18.8K | — | — | — | — | 225.0K | 0.00% | ↗ |
| 74 | 2011 | Thomas Hazel Senior Vice | 206.3K | 18.8K | — | — | — | — | 225.0K | 0.00% | ↗ |
| 75 | 2010 | Karl Johe Chief Scientific Officer | 422.1K | 253.3K | 316.6K | 316.6K | — | 6.0K | 1.31M | 48.17% | ↗ |
| 76 | 2010 | I. Richard Garr Chief Executive President, General Counsel (“PEO”) | 407.0K | 204.2K | 345.3K | 305.3K | — | 6.0K | 1.27M | 51.31% | ↗ |
| 77 | 2010 | John Conron Chief Financial Officer | 225.0K | 18.8K | 114.0K | 76.5K | — | 6.0K | 440.3K | 43.27% | ↗ |
| 78 | 2010 | Thomas Hazel Senior Vice President of Research | 180.0K | 15.0K | — | — | — | — | 195.0K | 0.00% | ↗ |
| 79 | 2009 | Karl Johe Chief Scientific Officer | 422.1K | 204.5K | 68.2K | — | — | 6.0K | 700.8K | 9.73% | ↗ |
| 80 | 2009 | Karl Johe Chief Scientific Officer | 422.1K | 204.5K | 68.2K | — | — | 6.0K | 700.8K | 9.73% | ↗ |
| 81 | 2009 | I. Richard Garr CEO | 407.0K | 52.6K | 157.8K | — | — | 48.7K | 666.0K | 23.69% | ↗ |
| 82 | 2009 | I. Richard Garr Chief Executive President, General Counsel (“PEO”) | 407.0K | 52.6K | 157.8K | — | — | 6.0K | 623.3K | 25.31% | ↗ |
| 83 | 2009 | John Conron Chief Financial Officer | 225.0K | 7.5K | 22.4K | — | — | 6.0K | 260.9K | 8.60% | ↗ |
| 84 | 2009 | John Conron Chief Financial Officer | 225.0K | 7.5K | 22.4K | — | — | 6.0K | 260.9K | 8.60% | ↗ |
| 85 | 2009 | Thomas Hazel Senior Vice President of Research | 180.0K | 15.0K | — | — | — | — | 195.0K | 0.00% | ↗ |
| 86 | 2009 | Thomas Hazel SVP of Research | 180.0K | 15.0K | — | — | — | — | 195.0K | 0.00% | ↗ |
| 87 | 2008 | I. Richard Garr CEO | 436.8K | 33.9K | 312.0K | 3.44M | — | 88.5K | 4.31M | 87.02% | ↗ |
| 88 | 2008 | I. Richard Garr Chief Executive President, General Counsel (“PEO”) | 436.8K | 307.7K | — | 3.44M | — | 88.5K | 4.27M | 80.49% | ↗ |
| 89 | 2008 | Karl Johe Chief Scientific Officer | 427.3K | 343.4K | — | 3.44M | — | 6.0K | 4.21M | 81.57% | ↗ |
| 90 | 2008 | Karl Johe Chief Scientific Officer | 427.3K | 341.7K | — | 3.44M | — | 6.0K | 4.21M | 81.60% | ↗ |
| 91 | 2008 | John Conron Chief Financial Officer | 208.8K | 18.8K | 60.0K | 1.13M | — | 4.5K | 1.42M | 83.63% | ↗ |
| 92 | 2008 | John Conron Chief Financial Officer | 208.8K | 18.8K | — | 1.13M | — | 4.5K | 1.36M | 82.91% | ↗ |
| 93 | 2008 | Thomas Hazel SVP of Research | 100.0K | 7.5K | — | 179.4K | — | — | 286.9K | 62.53% | ↗ |
| 94 | 2007 | Dr. Karl Johe Chief Scientific Officer | 425.3K | 186.1K | — | 570.5K | — | 31.6K | 643.0K | 88.72% | ↗ |
| 95 | 2007 | Karl Johe Chief Scientific Officer | 345.0K | 26.8K | — | — | — | — | 636.6K | 0.00% | ↗ |
| 96 | 2007 | I. Richard Garr Chief Executive President, General Counsel (“PEO”) | 357.0K | 26.8K | — | — | — | 33.4K | 417.1K | 0.00% | ↗ |
| 97 | 2007 | I. Richard Garr Chief Executive Officer (Principal Executive Officer) | 357.0K | 26.8K | — | — | — | 33.4K | 417.1K | 0.00% | ↗ |
| 98 | 2007 | John Conron Chief Financial Officer | 80.0K | 10.0K | — | — | — | — | 405.0K | 0.00% | ↗ |
| 99 | 2007 | Merrill Solomon | 132.0K | — | — | — | — | 31.6K | 163.6K | 0.00% | ↗ |
| 100 | 2006 | I. Richard Garr Chief Executive Officer (Principal Executive Officer) | 336.8K | 186.1K | — | — | — | 31.6K | 554.5K | 0.00% | ↗ |
| 101 | 2006 | Dr. Karl Johe Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 102 | 2006 | Merrill Solomon | — | — | — | — | — | — | — | — | ↗ |
| 103 | 2006 | John Conron Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1M | male |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 704.0K | male |
| James Izanec | VP & Head of Clinical Development | — | — |
| Joerg Heyer | Head of Translational Science & Medicine | — | — |
| Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | — | male |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | — | male |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | — | male |
| Sharon Skare | Vice President & Global Head of Clinical Operations | — | female |
| Daniel J. Larkins | Head of Global Regulatory Affairs | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PALI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
